Ashley Crew, M.D.
NPI 1942536834 · Dermatology Physician · Los Angeles, CA
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1942536834
- Entity type
- Individual
- Primary specialty
- Dermatology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Female
- Sole proprietor
- No
- License
- A115220 (CA)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
16 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
2 documented practice locations
- Medicare service volume (vs. specialty peers)25% of score
507 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 176 | $139 |
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 157 | $8 |
| Destruction of Precancer Skin Growth, 1 Growth17000 | 58 | $62 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 46 | $98 |
| Biopsy of Related Skin Growth, First Growth11102 | 35 | $109 |
| Destruction of Skin Growth, 1-14 Growths |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 8 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Ketoconazole | 40 | 22 |
| Triamcinolone Acetonide | 29 | 17 |
| Tacrolimus | 17 | — |
| Betamethasone/Propylene Glycbrand: Betamethasone Diprop Augmented | 15 | — |
| Clindamycin Phosphate | 12 | — |
| Hydroxychloroquine Sulfate | 12 | — |
| Mycophenolate Mofetil | 12 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$279 across 10 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Additional practice locations (1)
- 1520 San Pablo StSuite 1000aLos Angeles, CA 90033-5310Phone: (323) 442-6200
Registry dates
- Enumerated
- 2009-10-27
- Last updated
- 2023-11-27
- Certified
- 2020-09-01
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.